Purpose {#sec1}
=======

The prevalence of skin cancer has been growing both worldwide and in Iran \[[@cit0001]\]. This trend in our country has been attributed to increased incidence of the histologic type of squamous cell carcinoma (SCC) \[[@cit0002]\]. The majority of skin malignancies are non-melanoma skin cancers (NMSC), including more than 95% of cases. Basal cell carcinoma (BCC) is the most common subtype, diagnosed in 75-80% of NMSCs, followed by SCC, comprising the majority of the remaining cases \[[@cit0003]\]. Various modalities have been proposed for the treatment of NMSC based on its stage, location, histologic type, and preferences of the dermatologists and technical availabilities of each center. These include cryotherapy, surgical excision, laser therapy, topical chemotherapy, photodynamic therapy, and radiotherapy. The surgical removal is commonly preferred method for most lesions due to its low recurrence rates, estimated at 5% \[[@cit0004],[@cit0005],[@cit0006]\]. The Mohs' micrographic surgery (MMS) is the surgical technique of choice to achieve the oncological cure, preserve function, and restore cosmesis \[[@cit0007]\]. However, radiotherapy is appropriate in patients in whom surgery may produce esthetic defects, or in those with comorbidities who are unable to undergo an invasive intervention. Additionally, it is indicated as an adjuvant treatment after surgery in cases of close or positive margins. The radiation therapy is as effective as surgical techniques other than MMS.

Various radiotherapy techniques have been developed to treat skin cancer such as superficial orthovoltage X-ray, electron beam, megavoltage photons, low-dose- or high-dose-rate brachytherapy, and the newly emerging electronic brachytherapy \[[@cit0008]\]. Orthovoltage X-rays, despite being efficient for delivering high doses to skin surface, are not accessible in most radiation therapy centers, particularly in middle-income countries, due to their limited clinical coverage and cost-effectiveness. Electron beam therapy is time-consuming due to individualized beam shaping and has dosimetric challenges in treating small fields \[[@cit0009]\].

Brachytherapy has been used for the treatment of malignancies since Curie and Becquerel discovered radium, and it was first applied for skin cancer treatment in 1899 \[[@cit0010]\]. Direct contact therapy was the technique of choice in the first few decades with a 10-year control rate of 73.8% \[[@cit0011]\]. By the mid-1940s, brachytherapy lost its popularity in the treatment of skin lesions \[[@cit0012]\], until the introduction of remote afterload machines in the 1960s \[[@cit0013]\]. One of the techniques used in modern brachytherapy is placing the radioactive sources on the body surface. To do so, custom molds are created from the surface of the lesion's location. Then, catheters are implanted into the molds for afterloading of the radioactive isotopes \[[@cit0014]\].

Among the non-surgical treatments of skin cancers, there is a scarcity of data on the efficacy and outcome of high-dose-rate brachytherapy (HDR-BT) with surface molds on Iranian population, where MMS is not widely available. Also, the global experience is growing and needs further works. Accordingly, we aimed to carry out a prospective observational study on the oncological and cosmetic outcomes as well as toxicity profiles of HDR-BT with surface molds on patients with NMSC.

Material and methods {#sec2}
====================

Patient characteristics {#sec2.1}
-----------------------

In this prospective study, all patients with pathologically proven NMSC, referring to the Cancer Institute of Imam Khomeini Hospital from September 2013 to August 2014 for definitive or adjuvant treatment with HDR-BT were included. The patients underwent clinical examination with fully exposed skin and imaging studies as indicated to rule out nodal/visceral metastasis. Indications of brachytherapy in these patients were: 1. definitive treatment of T1-2 N0 tumors; 2. adjuvant treatment after surgical excision with a positive margin or residual (microscopic or gross) disease. Patients were excluded from the study if their lesions were thicker than 1 cm, extended to the periosteum or brain parenchyma, or metastasized to the lymphatics or distant viscera. Therefore, thorough explanations were given to the eligible patients on the aims of the study, its protocol, possible complications, and the importance of such survey. An informed written consent was obtained from the subjects willing to participate.

Treatment customization and planning {#sec2.2}
------------------------------------

After initial examinations, the physicians had to draw the treatment region of interest (ROI) on the skin surface. The ROI was the visible tumor plus a 1 to 2 cm radial margin. For the adjuvant cases, surgical bed with zero to one cm margin depending on the status of surgical margins formed the ROI. This drawing represented the mold periphery. Alginate was used for creating the mold. After mold formation, a piece of metal wire was placed at the edges. The catheters were implanted in the mold. The number of catheters and their distribution was determined based on the size of the tumor/tumor bed and its location. The catheters were placed with 1 cm-space from each other in a single plane. Plastic tube applicators (French 5) were used for afterloading of radioactive sources. Computed tomography (CT) simulation with 1 mm thickness slices was made for planning with the mold in place. Clinical target volume was drawn in the Flexiplan software version 2.6 (Isodosecontrol BV., Veenendaal, The Netherlands) according to the metal wire visible in images. The depth of the desired CTV was based on imaging findings (simulation CT or pre-treatment magnetic resonance imaging \[MRI\]). The maximum allowed depth was 10 mm from the skin surface. Paris system dosimetry was used for planning. A radiation oncologist controlled the treatment plan concerning D~90~ (the dose that 90% of the target volume receives), V~100~ (the volume receiving 100% of the prescribed dose), and conformity index (≥ 70% was considered acceptable). Flexitron (Elekta) machine was used for afterloading the radionuclide sources (^192^Ir) to the treatment positions. [Figure 1](#f0001){ref-type="fig"} shows a finalized three-dimensional plan in one of our patients with scalp BCC who underwent adjuvant radiotherapy due to positive surgical margin.

![**A)** The digital reconstruction radiograph of a patient with scalp basal cell carcinoma. The picture shows the surface mold placed over the scalp encompassing after-loading catheters. **B)** The dose distribution of the finalized 3D plan in axial, sagittal, and coronal planes. The yellow, blue, and the red lines represent D~200~, D~150~, and D~100~, respectively. The tiny crosses show the planning target volume](JCB-10-32734-g001){#f0001}

Follow-up {#sec2.3}
---------

Patients were followed for 2 years after treatment. Based on the guidelines of Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) \[[@cit0015]\], acute toxicity (erythema and wet desquamation) was evaluated through examination at day one, 1, and 3 months after the treatment. Similarly, the patients were examined after 6 months, 1 year, and 2 years post-treatment for an incident of late toxicity (atrophy and pigmentation). The patients were also evaluated for response to treatment, cosmetic results, and signs of recurrence. Examination and observations were completed by two radiation oncologists. Suspected recurrences were confirmed by punch biopsy and pathologic review.

Outcome measures {#sec2.4}
----------------

The primary outcomes in this study were acute and late complications. The secondary outcomes included response to treatment, local control, and overall survival and cosmetic results. Overall survival was defined as the fraction of patients who survived after the end of radiotherapy to the end of the first or second year of follow-up. Local control rate was defined as the percentage of patients without persistent/residual lesions or recurrence in the same site one or two years after the treatment. The cosmetic results were assessed by two physicians based on the tool that was developed by authors ([Table 1](#t0001){ref-type="table"}). We defined two cosmetics groups for simplicity and less inter-observer bias.

###### 

The tool for the assessment of the cosmetic results by the physician

  Cosmetic assessment group                        Items
  ------------------------------------------------ -----------------------------
  Good/excellent (all of the items)                No to mild telangiectasia
  No to mild fibrosis                              
  No to mild hypo-or hyper-pigmentation            
  Bad (either of the items)                        Moderate to severe fibrosis
  Skin contracture                                 
  Moderate to severe hypo- or hyper-pigmentation   

Statistical analysis {#sec2.5}
--------------------

The patients were subdivided into two groups including definitive and adjuvant radiotherapy for comparison. χ^2^ test was used to compare the rate of treatment-related toxicity between groups. Kaplan-Meier method was applied for estimation of actuarial survival rate and curves. We used log-rank test to compare survival rates between groups. Actuarial rates of overall survival and local failure were calculated based on the time interval from the last radiotherapy session to the last uneventful follow-up, or all-cause mortality and the date of failure, respectively. SPSS software version 22 (IBM Corp., Chicago, IL, USA) was used for all analyses. The level of significance for all statistical tests was placed at 0.05. Time-event rates were presented with confidence interval 95% (CI 95%).

Results {#sec3}
=======

Patients and tumors characteristics {#sec3.1}
-----------------------------------

A total of 60 patients were recruited for the study. Male to female ratio was 40 : 20, and the BCC to SCC ratio was 45 : 15. The median age was 71 years, ranging from 37 to 100 years. The most and least frequent sites of involvement were scalp (33%) and eyelid (3%), respectively. The median tumor size and thickness were 3 cm (range, 0.5-12) and 0.5 cm (range, 0.1-1), respectively. The intention of brachytherapy was definitive in 42 patients (70%) and adjuvant in the remaining. As presented in [Table 2](#t0002){ref-type="table"}, there was no significant difference between the two groups of definitive and adjuvant treatment in terms of gender, age, the situation of the tumor, or pathology of lesion.

###### 

General characteristics of the patients and the treatment parameters

  Qualitative variables        Total frequency (%)          Group                             *p* value                                       
  ---------------------------- ---------------------------- --------------------------------- ------------------------------- --------------- -------
  Gender                       Female                       20 (33.3)                         14 (33.3)                       6 (33.3)        1.000
  Male                         40 (66.7)                    28 (66.7)                         12 (66.7)                                       
  Age group                    ≤ 70                         29 (48.3)                         20 (47.6)                       9 (50.0)        0.866
  \> 70                        31 (51.7)                    22 (52.4)                         9 (50.0)                                        
  Location                     Face                         19 (31.7)                         11 (26.2)                       8 (44.4)        0.132
  Scalp                        20 (33.3)                    13 (31.0)                         7 (38.9)                                        
  Nose                         15 (25.0)                    14 (33.3)                         1 (5.6)                                         
  Ear                          4 (6.7)                      2 (4.8)                           2 (11.1)                                        
  Eyelid                       2 (3.3)                      2 (4.8)                           0 (0.0)                                         
  Pathology                    BCC                          45 (75.0)                         33 (78.6)                       12 (66.7)       0.347
  SCC                          15 (25.0)                    9 (21.4)                          6 (33.3)                                        
  **Quantitative variables**   **Total mean (std. dev.)**   **Definitive mean (std. dev.)**   **Adjuvant mean (std. dev.)**   ***p* value**   
  Duration (days)                                           15.8 (4.2)                        16.0 (4.1)                      15.4 (4.3)      0.646
  Total dose (Gy)                                           39.6 (5.4)                        38.8 (5.4)                      41.5 (4.9)      0.064
  Total dose EQD~2~ (Gy)                                    44.9 (7.7)                        42.9 (6.7)                      49.6 (8.2)      0.002
  Number of fractions                                       11 (1.4)                          11 (1)                          11 (1)          0.728
  Dose per fraction (Gy)                                    3.6 (0.6)                         3.5 (0.6)                       3.8 (0.7)       0.228
  D~90~ (Gy)                                                3.6 (0.7)                         3.5 (0.7)                       3.8 (0.7)       0.170
  V~100~ (cm^3^)                                            34.9 (35.5)                       29.7 (34.8)                     47.1 (35.1)     0.088

BCC -- basal cell carcinoma, SCC -- squamous cell carcinoma, EQD~2~ (Gy) -- equivalent dose at 2 Gy, D~90~ (Gy) -- the minimum dose received by 90% of the target volume, V~100~ (cm^3^) -- the percentage of the target volume receiving 100% of the prescribed dose or more

Dose and planning characteristics {#sec3.2}
---------------------------------

The characteristics of prescribed total dose, dose per fractions and D~90~ and V~100~ are presented in [Table 2](#t0002){ref-type="table"}. The median dose/fraction was 3 Gy in the definitive, and 4 Gy in the adjuvant setting. The range of total physical dose was between 30 and 52 Gy. This dose was prescribed in a minimum of 10 and a maximum of 13 fractions. The median EQD~2~ was 42.2 Gy (range, 33-61), 42.2 Gy, and 54.4 Gy in all, definitive, and adjuvant groups, respectively. The median V~100~ was 14.5 ml (range, 2.6-152.8) and 38.5 ml (range, 4.9-129.5) in the definitive and adjuvant settings, respectively.

As evident in [Table 2](#t0002){ref-type="table"}, no significant difference was observed between the two groups of definitive and adjuvant in quantitative treatment parameters measured, except for total EQD2 dose that was higher in the adjuvant setting.

Post-treatment complications {#sec3.3}
----------------------------

### Acute toxicity {#s3c1}

One day after treatment, 26 patients (43.3%) had grade 1-2, and 31 (51.7%) experienced grade 3-4 acute toxicity. Although the rate of grade 3-4 toxicities among the patients who underwent brachytherapy as definitive treatment was higher than the adjuvant group, the differences were not statistically significant. One month after treatment, 25% of patients were found to have grade 3-4 toxicities. By the end of third month, this figure decreased to 6.7%. Similarly, the rates of toxicities were higher in the definitive group, although the differences were non-significant ([Table 2](#t0002){ref-type="table"}).

### Late toxicity {#s3c2}

Patients were assessed for the late toxicities at 6 months, one year, and two years post-treatment. More than half of patients (50.8%) had signs of late grade 1-2 toxicity at 6 months follow-up, which decreased to 43.1% after 1 year. Nevertheless, only one patient showed signs of grade 3-4 toxicity, which was resolved by the 2^nd^ year of follow-up. Thus, the rate of late grade 3-4 toxicity was 1.6%, 1.6%, and 0% at 6^th^ month, 1^st^ year, and 2^nd^ year of follow-up, respectively. Definitive and adjuvant groups were not significantly different from each other considering the rate and grade of late toxicities ([Table 3](#t0003){ref-type="table"}).

###### 

Acute and chronic toxicities and cosmetic results of the treatment

                             Total frequency (%)        Group         *p* value                            
  -------------------------- -------------------------- ------------- ------------ ----------- ----------- -------
  **Acute toxicity**         One day after treatment    No toxicity   3 (5.0)      1 (2.4)     2 (11.1)    0.358
  Grade 1-2                  26 (43.3)                  19 (45.2)     7 (38.9)                             
  Grade 3-4                  31 (51.7)                  22 (52.4)     9 (50.0)                             
  1 month after treatment    No toxicity                23 (38.3)     17 (40.5)    6 (33.3)    0.869       
  Grade 1-2                  22 (36.7)                  15 (35.7)     7 (38.9)                             
  Grade 3-4                  15 (25.0)                  10 (23.8)     5 (27.8)                             
  3 months after treatment   No toxicity                44 (73.3)     30 (71.4)    14 (77.8)   0.397       
  Grade 1-2                  12 (20.0)                  10 (23.8)     2 (11.1)                             
  Grade 3-4                  4 (6.7)                    2 (4.8)       2 (11.1)                             
  **Late toxicity**          6 months after treatment   No toxicity   29 (49.2)    18 (43.9)   11 (61.1)   0.417
  Grade 1-2                  29 (49.2)                  22 (53.7)     7 (38.9)                             
  Grade 3-4                  1 (1.7)                    1 (2.4)       0 (0.0)                              
  1 year after treatment     No toxicity                33 (56.9)     21 (51.2)    12 (70.6)   0.361       
  Grade 1-2                  24 (41.4)                  19 (46.3)     5 (29.4)                             
  Grade 3-4                  1 (1.7)                    1 (2.4)       0 (0.0)                              
  2 years after treatment    No toxicity                27 (51.9)     16 (44.4)    11 (68.8)   0.138       
  Grade 1-2                  25 (48.1)                  20 (55.6)     5 (31.3)                             
  Grade 3-4                  0 (0.0)                    0 (0.0)       0 (0.0)                              
  **Cosmetic results**       After 1 year               Bad           3 (5.2)      3 (7.3)     0 (0.0)     0.548
  Good                       55 (94.8)                  38 (92.7)     17 (100.0)                           
  After 2 years              Bad                        2 (3.8)       2 (5.6)      0 (0.0)     0.336       
  Good                       50 (96.2)                  34 (94.4)     16 (100.0)                           

Clinical outcomes {#sec3.4}
-----------------

### Cosmetic results {#s3d1}

By the end of the first year, out of 58 live patients, 55 (94.8%) were found to have a good/excellent cosmetic outcome. Accordingly, this rate was found to be 92.7% in the definitive group and 100% in the adjuvant group. By the end of 2^nd^ year of follow-up, the percentage of good/excellent cosmetic outcome increased to 96.2% in 52 individuals, 94.4% in definitive, and 100% in adjuvant group (*p* = 0.961).

### Response to treatment {#s3d2}

Among patients in the definitive group after 1 month, the disease was stable in only 1 patient (2.4%), two patients (4.8%) showed partial response, and remaining 92.9% had a complete response to the treatment. By the 3^rd^ month, one of the partial responders was converted to complete, comprising 40 patients (95.2%) with complete response, 1 (2.4%) with partial response, and 1 (2.4%) with stable disease. The rate of clinical response was not associated with total dose or dose/fraction.

### Local control {#s3d3}

The lesions recurred in 2/18 patients (11.1%) who underwent adjuvant treatment. The recurrences were treated by surgical excision. Among patients undergoing definitive therapy, 2/42 (4.7%) experienced local failure after 3 months. In both groups, no other recurrences occurred until the end of 2 years follow-up. As depicted in [Figure 2](#f0002){ref-type="fig"}, the 2-year actuarial local control rate was calculated to be 95% (CI 95%: 89-100) in the definitive group, and 88% (CI 95%: 74-100) in the adjuvant group.

![The Kaplan-Meyer graph for actuarial local control. The blue and green lines represent definitive and adjuvant treatments, respectively](JCB-10-32734-g002){#f0002}

### Overall survival {#s3d4}

Median follow-up time was 2 years (range, 3-24 months). During this time, six persons died (1 by 6 months, 2 by the first year). Only one of these patients who underwent definitive HDR-BT for scalp lesion deceased because of their disease (after recurrence), and the other five died due to other causes than the malignancy. The 2-year overall survival (OS) rate was 87%, 86%, and 89% in total, definitive, and adjuvant groups, respectively.

### Effect of dosimetric parameters on outcomes {#s3d5}

As shown in [Table 4](#t0004){ref-type="table"} and [5](#t0005){ref-type="table"}, among patients undergoing definitive brachytherapy, higher dose per fraction and V~100~ were associated with a trend toward a higher frequency of grade 2 or greater late toxicities, with *p* values less than 0.1 and 0.01, respectively. After multivariate analysis, only V~100~ \> 15 ml was independent predictor of late toxicity in definitive cases. Otherwise, in both univariate and multivariate analyses, there were no significant associations among the parameters, and late toxicity, acute toxicity, cosmetic results, and local failure in either definitive or adjuvant settings.

###### 

Effect of dosimetric parameters on outcomes

  Setting             Dosimetric parameter   Grade 2-4 acute toxicity   Grade 2-4 late toxicity   Bad cosmetic results   Local failure   
  ------------------- ---------------------- -------------------------- ------------------------- ---------------------- --------------- -------
  Definitive          Dose/fraction          ≤ 3 Gy                     18 (85.7)                 1 (4.8)                1 (4.8)         0 (0)
  \> 3 Gy             19 (90.5)              5 (25)                     2 (10)                    2 (9.5)                                
  *p* value           0.99                   0.09                       0.60                      0.49                                   
  Total dose EQD~2~   ≤ 42.25 Gy             27 (84.4)                  5 (15.6)                  3 (9.4)                2 (6.2)         
  \> 42.25 Gy         10 (100)               1 (11.1)                   0 (0)                     0 (0)                                  
  *p* value           0.31                   0.99                       0.99                      0.99                                   
  V~100~              ≤ 15                   17 (81)                    0 (0)                     0 (0)                  0 (0)           
  \> 15               20 (95.2)              6 (30)                     3 (15)                    2 (9.7)                                
  *p* value           0.34                   0.01                       0.11                      0.49                                   
  Adjuvant            Dose/fraction          ≤ 3.5 Gy                   6 (66.7)                  1 (10)                 0 (0)           0 (0)
  \> 3.5 Gy           6 (75)                 1 (12.5)                   0 (0)                     2 (25)                                 
  *p* value           0.99                   0.99                       0.99                      0.18                                   
  Total dose EQD~2~   ≤ 46.67 Gy             5 (55.6)                   2 (22.2)                  0 (0)                  0 (0)           
  \> 46.67 Gy         7 (87.5)               0 (0)                      0 (0)                     2 (22.2)                               
  *p* value           0.29                   0.47                       0.99                      0.47                                   
  V~100~              ≤ 38.5                 4 (50)                     0 (0)                     0 (0)                  0 (0)           
  \> 38.5             8 (88.9)               2 (22.2)                   0 (0)                     2 (22.2)                               
  *p* value           0.13                   0.47                       0.99                      0.47                                   

EQD2 (Gy) -- equivalent dose at 2 Gy, V~100~ (cm^3^) -- the percentage of the target volume receiving 100% of the prescribed dose or more

###### 

Characteristics of patients with local failures

                  Setting      Time of evaluation   Physical Dose/no of fractions   Dose/fraction   EQD~2~   V~100~ (ml)   Histologic type   Location   Age   Gender
  --------------- ------------ -------------------- ------------------------------- --------------- -------- ------------- ----------------- ---------- ----- --------
  1^st^ Patient   Definitive   3 months             45/10                           4.5             42.25    152.8         BCC               Scalp      77    Male
  2^nd^ Patient   Definitive   3 months             48/12                           4               39.38    64            BCC               Scalp      60    Male
  3^rd^ Patient   Adjuvant     3 months             45/10                           4.5             54.38    53.6          BCC               Scalp      50    Female
  4^th^ Patient   Adjuvant     3 months             45/10                           4.5             54.38    53.6          BCC               Face       50    Female

EQD~2~ (Gy) -- equivalent dose at 2 Gy, V~100~ (cm^3^) -- the percentage of the target volume receiving 100% of the prescribed dose or more, BCC -- basal cell carcinoma

Discussion {#sec4}
==========

The outcome and cosmetic results of HDR-BT along with its associated acute and late toxicity were assessed in this prospective study conducted on patients with NMSC. The age distribution of our patients was the same in the adjuvant and definitive groups. One could presume that patients in the adjuvant groups should be significantly younger. This presumption roots in the potential risk of radiation-induced second neoplasms. The reason is that the standard Mohs's surgery is not routinely carried out in most parts of Iran. At present, extensive surgical excisions to achieve wide negative margins are not associated with good cosmetic results, especially in the face. Thus, many of the young patients preferred radiation therapy over surgery accepting the risk of secondary malignancies. There was a relative wide dose range in our study. In the beginning, we used bigger dose per fractions of 4-4.5 Gy and higher total dose of about 52 Gy. But, gradually, by observing some acute complications we lowered the dose/fractions and total dose to uniform 39 Gy in 13 daily fractions five days a week. This is the explanation for our dose range. The D~90~ should receive the prescribed dose. Our initial patients received adjuvant radiotherapy and by the compilation of the experiences, we started definitive treatment. Therefore, the total EQD~2~ dose was significantly higher in the adjuvant group. Besides, our adjuvant cases were all patients with microscopic or macroscopic residue after surgery who were not amenable to further resections and had a high chance of progression without adjuvant treatments. We added that results of the analysis of the link between dosimetric parameters including dose/fraction, total dose, and V~100~ with toxicities. Interestingly, we found that post-treatment/fraction over 3 Gy was associated with higher late toxicity in the definitive setting. Thus, this is a possible explanation for our high toxicity rates. Also, the mean depth of the lesions studied was more elevated than similar investigations. When treating deep-seated tumors, the superficial skin places in D~100~ or D~150~ and consequently, receives higher doses than the most in-depth segment. This non-uniformity (over 3%) could be another explanation for our higher toxicities compared to the literature \[[@cit0016]\].

In similar studies reporting the results of HDR-BT treatment with surface molds, the range of local control varied between 87% to 100% \[[@cit0017],[@cit0018],[@cit0019],[@cit0020]\]. Considering CI 95%, our 2-year local control was in agreement with other studies. Although, several factors have been proposed for differences observed in local control rates; these include tumor size (small vs. large), location (plain vs. curved surfaces), treatment margin, and histology (BCC vs. SCC). In our study, the majority of recurrent cases were large lesions on the scalp with BCC histology. Our small sample size limited the potential to compare the effect of these factors on local control. Nevertheless, there was no statistically significant difference between definitive and adjuvant treatment groups.

Our cosmetic results with HDR-BT were quite promising, with more than 95% of cases showing good/excellent results after two years of follow-up. Other studies using HDR-BT or electronic brachytherapy achieved similar results \[[@cit0008],[@cit0021],[@cit0022]\].

HDR-BT was quite tolerable by our patients, with meager rates of severe acute and late toxicities. Theoretically, some investigators believed that large fraction size used with HDR-BT might be associated with higher late toxicity \[[@cit0019],[@cit0020],[@cit0021]\]. Although several other investigations counteracted this belief, our study suggested that the lower dose/fraction, the better late toxicity profile. Overall, the results of all the available literature on this subject, including the present study indicates that HDR-BT is associated with good treatment outcomes and acceptable acute and late complications. Therefore, this modality could be considered as a mainstay treatment for NMSCs located on the nose, eyelid, ear, and any other region where surgical excision might be difficult, or the required anesthesia harbors high-risk for patient life. This is particularly the issue in the elderly and frail patients who share the most substantial contribution to the prevalence of skin cancers \[[@cit0023]\].

Conclusions {#sec5}
===========

As long as the dose/fraction is kept below 3 Gy/fraction, HDR-BT is an attractive modality to manage skin cancers in the head and neck region with acceptable toxicity and promising cosmetic results. Longer follow-up is needed to establish the long-term local control rates confidently.
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